Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.64 |
| ▸ | QPCT | Q16769 | 1/20 | 0.64 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.64 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394308 | 0.91 | CYP11B1 (0.83) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL10975737 | 0.85 | CYP19A1 (0.74) | CYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL3092795 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL12205 | 0.83 | CYP11B1 (1.00) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL24733003 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL13153034 | 0.83 | CYP11B1 (0.66) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL12245400 | 0.83 | CYP11B1 (0.66) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL306338 | 0.82 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP19A1CYP1A2POLB | |
| SCHEMBL14647046 | 0.80 | CYP11B1 (0.71) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 | |
| SCHEMBL11488635 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2ADRA2CCYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| CN-101784520-B | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-02 | — | — | CN | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| CN-101784520-A | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2010-07-21 | — | — | CN | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | CYP11B1 997/4885CYP11B2 754/4885ADRA2C 4215/4885 |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | CYP11B1 396/4885CYP11B2 532/4885ADRA2C 3593/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | CYP11B1 997/4885CYP11B2 754/4885ADRA2C 4215/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | CYP11B1 1164/4885CYP11B2 417/4885ADRA2C 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.